fig1

Figure 1. Comparison between Liver Imaging Reporting and Data System (LI-RADS) treatment response algorithm and modified Response Evaluation Criteria in Solid Tumors (mRECIST) to assess response. In the LR-Treatment response algorithm (LR-TRA), viable tumor is characterized by the presence of residual nodular or thick rim arterial phase hyperenhancement, or nodular or thick rim washout, or any enhancement that is similar to the pretreatment tumor characteristics in any imaging phase. In mRECIST, only residual arterial phase hyperenhancement is considered viable tumor. In both systems, residual tumor is measured as the longest diameter of the enhancing component of a treated tumor. In the LR-TRA, response is assessed on a per lesion basis, whereas in mRECIST, response is assessed on a per patient basis.